Modulating Alpha-Synuclein Toxicity via Intermediary Protein Targets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease and other synucleinopathies lack effective methods to inhibit alpha-synuclein mediated toxicity and aggregation, which contribute to neuronal dysfunction and death.
Innovation Solution
Identification and modulation of specific genes and proteins, such as PPP2CB, PPP6C, and KLF11, through compounds that inhibit or enhance their expression or activity to mitigate alpha-synuclein toxicity, using nucleic acids, small molecules, or osmolytes like trehalose to treat or prevent synucleinopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Parkinson's disease are used, then symptomatic relief is achieved, but effective inhibition of alpha-synuclein mediated toxicity and aggregation is not provided
Solution Approach 1:
The patent identifies specific genes and proteins (PPP2CB, PPP6C, KLF11) as intermediary targets that mediate alpha-synuclein toxicity. By modulating these intermediary proteins rather than directly targeting alpha-synuclein, the invention achieves effective toxicity inhibition through established molecular pathways.
Solution Approach 2:
The invention changes the molecular parameters of the disease mechanism by targeting specific protein expression and activity levels. Compounds are designed to alter the expression or activity of intermediary proteins (PPP2CB, PPP6C, KLF11), thereby changing the toxicological parameters of alpha-synuclein aggregation and neuronal damage.
2Stability of the object's composition
If alpha-synuclein aggregation is allowed to proceed, then fibril formation occurs, but neuronal dysfunction and death are accelerated
Solution Approach 1:
The patent converts the harmful aggregation process into a beneficial controlled process by targeting specific intermediaries (PPP2CB, PPP6C) that regulate fibril formation. By modulating these intermediaries, the invention transforms uncontrolled toxic aggregation into controlled, less harmful fibril formation, thereby protecting neurons.
Solution Approach 2:
The invention uses intermediary proteins (PPP2CB, PPP6C, KLF11) as mediators between alpha-synuclein aggregation and neuronal damage. These intermediaries control the aggregation process, allowing fibril formation to occur in a regulated manner that prevents direct neuronal toxicity while maintaining structural integrity.
3Ease of manufacture
If no specific target proteins are identified, then treatment development is simplified, but therapeutic efficacy is reduced
Solution Approach 1:
The patent segments the complex alpha-synuclein toxicity pathway into specific targetable components (PPP2CB, PPP6C, KLF11). By dividing the overall toxicity mechanism into discrete protein targets, the invention simplifies drug development while maintaining high therapeutic efficacy through focused molecular intervention.
Solution Approach 2:
The invention changes the development approach by shifting from non-specific to specific parameter targeting. By identifying and targeting specific protein parameters (expression levels, activity of PPP2CB, PPP6C, KLF11), the patent achieves both simplified development through clear targets and high efficacy through precise molecular modulation.
Data Source
AI summary
Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.